NCT03530683: Phase 1: A Trial of TTI-622 in Patients With Advanced Hem. Malignancies (TTI-622-01)

NCT03530683: Phase 1: A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies (TTI-622-01)

ClinicalTrials.gov Identifier: NCT03530683

Sponsor

Trillium Therapeutics Inc.

Multicenter, open-label, phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in subjects with Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma.

Multiple Locations

International Study

---

ClinicalTrials.gov Identifier: NCT02899052

Official Title: A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients With Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma

First Posted : May 21, 2018

https://clinicaltrials.gov/ct2/show/NCT03530683

---